Asteri's new CEO, Benet Irish, has grabbed the headlines of Australia's most trusted pharma news source, Pharma in Focus, this week.
Lamenting the fact that there has been a recent mass exodus of Australian country leaders (moving up the career ladder with their own company or a rival)l, the article celebrates Mr Irish's decision to forge a new path leading an Aussie start-up.
Five months after finishing up as General Manager ANZ for Teva Pharmaceuticals, Mr. Irish, was clearly optimistic about the opportunities on his home soil and vocal about his belief that Australia remains an under-developed market for global biopharmaceutical companies with products in the rare disease, CNS and sleep.
"Every day, thousands of Australians are diagnosed with life-changing medical conditions. Yet many lack access to the best and latest medicines simply because of where they live," he says.
"With over two decades of experience and expertise navigating this landscape, the Asteri team passionately believe that everyone in Australia should benefit from approved medicines equally."
"At Asteri Pharma, we are on a mission to redefine partnership and the commercialisation of medicines to improve patient access across Australia, specifically addressing diseases with high unmet need."
"Our commitment is to collaborate, partner and facilitate access to innovative medicines for patients regardless of where in Australia they live."
With over 20 country leaders leaving their roles in the Australian pharma industry in the last 12 months, Mr Irish's belief in Asteri and its mission is clearly good news for local patients and health care professionals alike.
Click the link to read the full article, Suprise role for ex-Aussie GM.
Comments